ArticleScientific reports2025
QbD-Driven preparation, characterization, and pharmacokinetic investigation of daidzein-l oaded nano-cargos of hydroxyapatite.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Research Progress on the Anti-Inflammatory and Antioxidant Effects of Daidzein: Its Mechanisms of Action in Related Diseases, and Related Nanoformulations to Enhance Its Bioavailability.Antioxidants (Basel, Switzerland) · 2026Review
- Pharmacotherapeutic potential of daidzein: insights into mechanisms and clinical relevance.Inflammopharmacology · 2025Review
- Mesoporous Silica-Loaded PCL-CHT Hybrid Membranes for Skin Regeneration.ACS applied materials & interfaces · 2025Article
- Integrating Quality by Design (QbD) in Phytosomal Drug Delivery: A New Era in Precision Phytotherapy.AAPS PharmSciTech · 2025Review
- Tumor-targeted hydroxyapatite nanoparticles for dual-mode diagnostic imaging and near-infrared light-triggered photothermal cancer therapy.bioRxiv : the preprint server for biology · 2025Article
- Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The repercussions of hormone replacement therapy (HRT) and bisphosphonates pose serious clinical challenges and warrant novel therapies for osteoporosis in menopausal women. To confront this issue, the present research aimed to design and fabricate daidzein (DZ); a phytoestrogen-loaded hydroxyapatite nanoparticles to mimic and compensate for synthetic estrogens and biomineralization. Hypothesizing this bimodal approach, hydroxyapatite nanoparticles (HAPNPs) were synthesized using the chemical-precipitation method followed by drug loading (DZHAPNPs) via sorption. The developed nanoparticles were optimized by "Design-Expert" software and underwent comprehensives in-vitro and in-vivo characterizations. The particle sizes of HAPNPs and DZHAPNPs were found to be 118.9 ± 0.15 nm and 129.3 ± 0.65 nm, respectively, consistent with their FESEM and TEM images. A notable entrapment efficiency of 87.23 ± 0.97% and drug release of 91 ± 0.85% from DZHAPNPs was observed over 90 h at pH 7.4. Moreover, the XRD and FTIR results confirmed the amorphization and compatibility of DZHAPNPs. TGA analysis indicated that the thermal stability of blank and drug-loaded nanoparticles was up to 900 °C. In an in vivo pharmacokinetic investigation, three-fold increased bioavailability of DZHAPNPs (AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.